CEO Executive AssistantPharmacy Benefit Management Coordination Requires Dedicated Administrative Infrastructure
Pharmacy benefit management coordination has become one of the most complex and financially consequential responsibilities for healthcare CEOs. PBM relationships and strategy sit at the intersection of drug pricing, formulary design, rebate contracting, specialty pharmacy management, and vertically integrated model evaluation, each a substantive domain in its own right, and together a program that generates enormous financial exposure and strategic complexity.
For healthcare CEOs, pharmacy benefit management coordination means overseeing the PBM contract relationship, engaging with formulary management decisions and the drug rebate programs that fund a significant portion of plan economics, monitoring specialty drug spend and utilization trends that drive cost volatility, managing relationships with drug manufacturers and rebate aggregators, and ensuring the board has the visibility and strategic context it needs to govern the pharmacy benefit program effectively.
The administrative demands of pharmacy benefit management coordination are substantial and do not simplify over time. Formulary changes require structured review and communication processes. Rebate contract cycles generate document management and negotiation coordination demands. Specialty drug spend reporting runs on a schedule that does not accommodate ad hoc CEO attention. An executive assistant who owns the scheduling, tracking, and briefing architecture around PBM coordination is the infrastructure that allows the healthcare CEO to lead this program strategically rather than reactively.
Scheduling PBM Contract Review Meetings
PBM contract relationships are among the largest and most complex vendor relationships that healthcare organizations manage. The financial terms of a PBM contract, including guaranteed discount levels, dispensing fees, administrative fees, rebate pass-through provisions, and audit rights, can represent hundreds of millions of dollars in annual economic impact for a large health plan or employer. The CEO’s engagement with PBM contract performance and contract renewal is a strategic priority, not a procurement function.
The EA establishes a PBM contract review cadence appropriate to the cycle of the relationship. In years when the PBM contract is not in active renewal, a quarterly contract performance review gives the CEO structured visibility into whether the PBM is meeting its guaranteed performance levels, whether the rebate and discount terms are being administered accurately, and whether the strategic relationship is functioning as intended. In contract renewal years, the review cadence intensifies: the EA schedules monthly reviews during the negotiation phase, coordinates internal preparation sessions before each negotiation meeting, and manages the documentation of negotiating positions and approved deal parameters.
Pre-meeting preparation for PBM contract reviews requires input from multiple internal stakeholders: the pharmacy benefits team on operational performance and formulary issues, the finance team on financial performance against guaranteed terms, and the legal team on contract compliance and audit findings. The EA establishes the materials submission timeline, reviews submitted materials for completeness, and ensures the CEO has a consolidated briefing that synthesizes the inputs from each team into a coherent picture of the PBM relationship’s current status.
Contract review meetings should also address the strategic context of the PBM relationship. As vertically integrated pharmacy models, direct manufacturer contracting, and PBM disintermediation strategies receive increasing attention from healthcare leaders, the CEO’s contract review engagement should include a periodic discussion of whether the current PBM relationship structure remains aligned with the organization’s long-term pharmacy benefit strategy. The EA builds these strategic discussion items into the agenda framework for contract reviews at the appropriate points in the contract cycle.
Coordinating Formulary Management and Drug Rebate Briefings
Formulary management is the clinical and commercial core of the pharmacy benefit program. Formulary placement decisions, tier assignments, prior authorization requirements, and step therapy protocols collectively determine which drugs members can access, at what cost-sharing level, and under what utilization management conditions. For healthcare CEOs, formulary management decisions are consequential both clinically and financially, and maintaining a CEO-level understanding of major formulary changes and their implications is essential.
The EA coordinates a structured formulary management briefing cadence that gives the CEO visibility into major formulary changes before they are implemented and communicated to members. These briefings should cover the drugs being added, removed, or repositioned on the formulary, the clinical rationale for the changes, the expected financial impact, and the member communication and provider notification plan.
Drug rebate briefings are a related but distinct function. Drug rebates are negotiated between the PBM (or, in some models, a rebate aggregator) and pharmaceutical manufacturers, and they represent a significant financial offset to drug costs. For large health plans and employer programs, rebate revenue can represent billions of dollars annually, and the terms under which rebates are negotiated, collected, and passed through to the plan or employer are often the most commercially significant provisions in the PBM contract.
The EA coordinates rebate briefings that give the CEO a clear view of the rebate program’s financial performance: rebates earned by drug category, rebates received versus guaranteed levels, formulary placement decisions driven by rebate strategy rather than clinical preference, and any changes in manufacturer rebate programs that could affect the plan’s rebate revenue. When rebate aggregators or group purchasing organizations are involved in the rebate program, the EA ensures the CEO understands the role and financial impact of those relationships.
For EAs who support healthcare CEOs managing the medical board relationships that intersect with formulary management through pharmacy and therapeutics committee oversight, medical board coordination provides a complementary framework for managing the governance connections between the P&T committee and the CEO’s PBM strategy engagement.
Rebate contracting cycles require a specific coordination function. When PBM formulary rebate contracts with manufacturers come up for renewal, or when new manufacturer rebate agreements are being negotiated, the EA manages the scheduling of internal review sessions, coordinates with the PBM on negotiation timelines, and ensures the CEO is briefed on the rebate negotiation strategy before any significant commercial engagement.
Tracking Specialty Drug Spend and Utilization Reporting Cycles
Specialty drug spend is the fastest-growing component of pharmacy benefit cost for most healthcare organizations. Specialty drugs for oncology, rare diseases, immunology, and gene therapy now account for more than half of total drug spend for many large health plans, and the trend line shows continued acceleration as innovative specialty therapies receive FDA approval and enter the market at prices that create significant financial exposure.
The EA maintains a specialty drug spend reporting calendar that reflects the monthly and quarterly cycles through which the CEO and the board receive visibility into specialty drug cost trends. Monthly specialty spend reports give the CEO a current view of per-member-per-month specialty cost, high-cost claimant trends, the drugs driving cost growth, and the utilization management program’s effectiveness in managing specialty drug access appropriately.
Monthly specialty spend reports should be structured for executive review, not as raw claims data extracts. The EA works with the pharmacy benefits team to ensure the report format gives the CEO the contextual analysis needed to make informed decisions: how does current specialty spend compare to the budget and prior year? Which therapeutic categories are driving variance? What is the pipeline of high-cost specialty drugs expected to receive FDA approval in the next 12 months, and what is the projected financial impact on the plan?
Quarterly utilization reporting provides a deeper view of the specialty drug program’s management effectiveness. Prior authorization approval rates, step therapy compliance, specialty pharmacy steering program results, and biosimilar adoption rates are all indicators of whether the utilization management program is working. The EA coordinates with the pharmacy benefits team to ensure quarterly utilization reports reach the CEO on a defined schedule and include the comparative context needed to evaluate whether performance is improving or deteriorating.
When individual high-cost specialty drug cases create financial exposure that warrants CEO awareness, the EA ensures those situations are escalated promptly. A single gene therapy claim can represent a multi-million-dollar financial event for the plan, and the CEO needs to be informed through internal channels, not from a board director who saw the financial report.
Managing Drug Manufacturer and Rebate Aggregator Relationship Meetings
The pharmaceutical manufacturer and rebate aggregator relationships that support the pharmacy benefit program operate at multiple levels of the organization, but the most strategically significant manufacturer engagements require CEO-level participation. Manufacturers of high-volume or high-cost drugs are significant commercial partners whose rebate offers, patient assistance programs, and formulary access strategies have material financial consequences for the health plan.
The CEO’s engagement with drug manufacturer relationships focuses on the strategic and commercial dimensions: the rebate and contracting relationship, the manufacturer’s approach to biosimilar competition, the pricing and access strategy for pipeline products, and any collaborative patient care or value-based contracting programs the manufacturer is proposing.
The EA manages the scheduling and preparation for manufacturer relationship meetings with the same rigor applied to other major vendor relationships. Before each manufacturer meeting, the EA prepares a briefing that covers the manufacturer’s drug portfolio and its position in the formulary, the current rebate relationship and its financial significance, any formulary or utilization management issues involving the manufacturer’s products, and the specific commercial discussion the CEO is entering.
Rebate aggregator relationships require a different preparation approach. Rebate aggregators provide a service to health plans by negotiating manufacturer rebates on a pooled basis, and the financial value of the relationship depends on the aggregator’s ability to achieve rebate levels that exceed what the plan could negotiate directly through the PBM. The CEO’s engagement with rebate aggregator partners should include a regular assessment of the aggregator’s financial performance, the drugs and categories covered by the aggregator’s rebate programs, and the strategic alignment between the aggregator’s formulary recommendations and the plan’s clinical and financial objectives.
According to McKinsey’s analysis of pharmacy benefit management and drug pricing dynamics, the financial stakes in PBM contracting and drug rebate management are expanding as specialty drug costs rise and as new models for drug pricing, including outcomes-based contracts and cell and gene therapy installment payment programs, require health plans to develop new contracting capabilities. Healthcare CEOs who are personally engaged in the strategic dimensions of PBM and manufacturer relationships are better positioned to navigate this evolving landscape than those who delegate it entirely to functional teams.
Preparing Board Presentations on PBM Strategy and Pharmacy Cost Trend
The CEO’s board presentations on pharmacy benefit management strategy must convey the financial scale and trajectory of the pharmacy benefit program, the strategic approach to PBM contracting and formulary management, the specialty drug cost challenge and the plan’s response, and the assessment of vertically integrated pharmacy models as a long-term strategic option.
The EA manages the board prep process for PBM strategy presentations with a structured timeline starting three weeks before each board meeting. They establish which elements of the pharmacy benefit update the CEO will present, who owns each data set and analysis, and when drafts are due for CEO review. Contributions from the pharmacy benefits, finance, legal, and clinical teams are consolidated by the EA with version control maintained throughout the drafting process.
Board presentations on PBM strategy should address the board’s most pressing concerns directly. What is the total pharmacy benefit cost and how does it compare to budget and industry benchmarks? What is the financial risk associated with specialty drug cost growth, and what is the plan doing to manage that risk? How does the current PBM relationship compare to market alternatives, and is the organization getting the contracted value? What is the strategic assessment of vertically integrated pharmacy models, and what is the timeline for completing that evaluation?
The vertically integrated pharmacy model evaluation deserves careful treatment in board presentations. Many large health systems, insurers, and employer programs are actively evaluating whether to acquire or develop in-house pharmacy benefit management capabilities as a response to PBM margin concerns and formulary management conflicts of interest. The board needs a clear view of the organization’s strategic posture on this question: what are the potential benefits of vertical integration, what are the capital and operational requirements, and what is the CEO’s recommended approach?
For EAs who support healthcare CEOs managing ambulatory care coordination programs where pharmacy access and medication adherence intersect with outpatient care management, ambulatory care coordination provides a framework for managing the connections between the pharmacy benefit program and outpatient care delivery.
The CEO’s talking points for the board pharmacy benefit presentation should directly address the questions directors are likely to raise about cost trend and strategic risk: What is our 3-year pharmacy cost trend projection, and what assumptions drive it? What is our exposure to a single high-cost specialty drug claim exceeding our stop-loss threshold? How confident are we that the PBM is administering our contract terms accurately, and what audit program do we have in place?
Pharmacy Benefit Management Coordination Rewards Administrative Precision
The administrative demands of pharmacy benefit management coordination span PBM contract oversight, formulary and rebate management, specialty drug spend tracking, manufacturer and aggregator relationship management, and board-level strategic reporting. Each function operates on its own cadence, involves different internal and external stakeholders, and generates decision points that require CEO engagement at the right level and with the right preparation.
Healthcare CEOs who invest in building the administrative infrastructure around pharmacy benefit management coordination consistently find that the EA’s discipline on scheduling, briefing, tracking, and follow-through is what allows them to stay strategically ahead of one of their organization’s most significant cost drivers. The pharmacy benefit program that runs on a documented, disciplined administrative rhythm is the one that achieves its financial performance targets, manages specialty drug cost effectively, and maintains the board’s confidence in the leadership team’s governance of this consequential program.
Pharmacy benefit management coordination is too financially significant and strategically complex to run without dedicated administrative infrastructure. The EA who owns that infrastructure is a genuine contributor to the healthcare organization’s financial performance and the CEO’s ability to lead the program with rigor and strategic clarity.